Alpha Signal Monitor - Daily Market Briefing | April 24, 2026
Daily Market Research Report
April 24, 2026
Alpha Signal Monitor
Welcome to your daily pre-market briefing. This report provides key insights on market opportunities and analyst perspectives to help identify potential alpha signals.
Today's Coverage: - Gold ETF Outlook: Institutional perspectives on gold-backed ETFs - Stock Ratings: Latest analyst ratings and target prices for our watchlist - IPO Calendar: Upcoming initial public offerings and market debuts
Watchlist Stocks: AAPL, MSFT, GOOGL, AMZN, NVDA, META, TSLA, AVGO, TSM
This report is generated using advanced AI research capabilities with real-time market data access.
Institutional Outlook: Gold ETFs (GLD, IAU, BAR) — As of April 24, 2026
Trading Idea: Buy Rationale (TL;DR): Most major institutions keep bullish end‑2026 gold targets ($5,000–$6,300/oz) and expect renewed ETF inflows as real yields ease and central‑bank demand stays strong, supporting physically backed gold ETFs such as GLD, IAU, and BAR.
Consensus across top research desks: (1) easing or steady‑to‑lower real rates into late‑2026 are supportive for non‑yielding assets; (2) central banks’ multi‑year reserve diversification has kept demand robust; (3) high public‑sector deficits and episodic geopolitical stress sustain a strategic bid for gold. UBS’s CIO still sees fresh highs in 2026 and end‑year ~$5,900/oz; BofA Global Research outlines a path to $5,000/oz in 2026 and documents gold’s tendency to rise when the Fed eases with CPI >2%; HSBC reiterates a constructive medium‑to‑long‑term view even after the March pullback. (ubs.com)
Key Drivers - Expected Fed easing and lower real yields into 2026 support gold prices and ETF demand. (business.bofa.com) - Central‑bank gold purchases remain a structural tailwind; 2025 demand exceeded 5,000t, and UBS projects sizable ETF inflows in 2026. (ubs.com) - Potential USD softness over the medium term is an additional support for gold. (expat.hsbc.com) - Supply growth is inelastic near term; investment demand is the main swing factor affecting ETF holdings/prices. (morganstanley.com)
| Institution | Stance | Price View | Key Evidence | Last Update | Source |
|---|---|---|---|---|---|
| Goldman Sachs | Overweight/Positive | End‑2026 target: $5,400/oz | GS retained a bullish view after the late‑Q1 selloff, reiterating an end‑2026 $5,400/oz target, driven by continued central‑bank buying and two more US rate cuts. (bloomberg.com) | 2026-03-31 | https://www.bloomberg.com/news/articles/2026-03-31/goldman-still-sees-gold-at-5-400-by-year-end-despite-downturn |
| Morgan Stanley | Overweight/Positive | 2026 forecast: $4,400/oz | MS Research revised its 2026 gold forecast up to $4,400/oz, citing likely USD weakness, renewed ETF inflows and ongoing central‑bank demand; notes risks if USD stays strong. (morganstanley.com) | 2025-10-22 | https://www.morganstanley.com/insights/articles/gold-price-forecast-rally-into-2026 |
| JP Morgan | Overweight/Positive | End‑2026 target: $6,300/oz | JPM raised its end‑2026 gold target to $6,300/oz, pointing to strong central‑bank and investor demand; JPM Global Research also highlights sizeable ETF inflows in 2026. (mining.com) | 2026-02-02 | https://www.mining.com/jpmorgan-sees-gold-price-reaching-6300-by-year-end/ |
| Bank of America | Overweight/Positive | Path to $5,000/oz in 2026 (avg ~ $4,400) | BofA Global Research lifted its 2026 gold outlook to $5,000/oz (avg ~ $4,400) on persistent macro tailwinds (deficits, diversification) and shows gold historically rises when the Fed eases with CPI >2%. (investing.com) | 2025-12-03 | https://business.bofa.com/content/dam/flagship/global-research/2026-economy-market-outlook-themes.pdf |
| Citigroup | Neutral/Tactical | Base case: grind lower; bull case: $5,000 by end‑2026; ~$6,000 by end‑2027 | Citi Research (Dec 2025) did not view gold as a great bullish trade near $4,200, with a base‑case drift lower; upside bull case sees $5,000 by end‑2026. A Jan 13, 2026 update cautioned that any early‑year surge above $5,000 could be vulnerable later in 2026. (citigroup.com) | 2026-01-13 | https://www.citigroup.com/global/insights/print/prospects-for-2026-goldilocks-performance-but-risks-linger |
| UBS | Overweight/Positive | End‑2026 target: $5,900/oz | UBS CIO expects fresh highs and maintains a $5,900/oz year‑end 2026 target; projects 2026 ETF inflows around 825t and views gold as a strategic mid‑single‑digit allocation. (ubs.com) | 2026-04-19 | https://www.ubs.com/global/en/wealthmanagement/insights/chief-investment-office/house-view/2026/weekly-key-messages/_jcr_content/root/contentarea/mainpar/toplevelgrid_1825995/col_2/textimage_copy.0899426504.file/dGV4dD0vY29udGVudC9kYW0vYXNzZXRzL3dtL2dsb2JhbC9jaW8vaG91c2Utdmlldy9kb2N1bWVudC9jYW4tZ29sZC1yZWFjaC1uZXctaGlnaHMtZW4tMTY1ODQ0My5wZGY%3D/can-gold-reach-new-highs-en-1658443.pdf |
| HSBC | Overweight/Positive (medium‑to‑long term) | - | HSBC Private Bank/Premier Wealth keeps a constructive medium‑to‑long‑term view; sees gold resuming its rally post‑conflict, underpinned by rising global debt and potential USD softness, while noting high prices weigh on jewelry/coin demand. (expat.hsbc.com) | 2026-04-20 | https://www.expat.hsbc.com/wealth/insights/fx-insights/fx-viewpoint/gold-to-resume-its-rally/ |
| Deutsche Bank | Overweight/Positive | 2026 target: $6,000/oz | DB reiterates that gold could reach ~$6,000/oz in 2026, with support from a weaker USD and strong central‑bank/investor demand (Reuters). (tradingview.com) | 2026-01-27 | https://www.tradingview.com/news/reuters.com%2C2026%3Anewsml_L1N3YS0CL%3A0-deutsche-bank-sees-gold-prices-reaching-6-000-per-ounce-in-2026/ |
Risk Considerations - Higher‑for‑longer rates or a re‑acceleration in real yields could cap gold/ETF upside. (expat.hsbc.com) - Sustained USD strength would pressure gold and delay ETF re‑accumulation. (expat.hsbc.com) - A slowdown or reversal in central‑bank buying would undermine the structural bid. (expat.hsbc.com) - Prolonged ETF outflows or weak retail/jewelry demand at high prices could mute rallies. (ubs.com)
Bias to accumulate gold ETF exposure on dips, given clustered Street targets at $5,000–$6,300/oz into year‑end 2026 and expectations for renewed ETF inflows as real yields ease. Prefer highly liquid, physically backed funds (GLD for depth; IAU/BAR for lower expense) and monitor real yields, DXY and weekly ETF holdings as key tactical signals.
Stock Ratings — U.S. Mega‑Cap Tech: Street Targets & Ratings (as of April 24, 2026)
Collected latest public targets/ratings from GS, MS, JPM, BAC, C, and WFC for the requested tickers. Ratings were normalized: Buy includes Overweight/Outperform; Hold includes Neutral/Equal‑Weight; Sell includes Underweight.
AAPL - Apple Inc.
Most houses remain Buy; BAC is Neutral. Recent GS note reaffirmed $330 PT.
| Institution | Rating | Target Price | Last Update | Notes | Source |
|---|---|---|---|---|---|
| Goldman Sachs | Buy | $330 | 2026-04-20 | Reiterated Buy into April quarter. | https://www.streetinsider.com/news.php?classic=1&id=26332787 |
| Morgan Stanley | Buy | $315 | 2026-03-12 | Reiterated Overweight. | https://www.marketbeat.com/stocks/NASDAQ/AAPL/forecast/ |
| JP Morgan | Buy | $325 | 2026-01-30 | Boosted from $315; Overweight. | https://www.marketbeat.com/stocks/NASDAQ/AAPL/forecast/ |
| Bank of America | Hold | $268 | 2026-04-17 | Reiterated Neutral. | https://www.marketbeat.com/stocks/NASDAQ/AAPL/forecast/ |
| Citigroup | Buy | - | 2026-04-21 | Reiterated Buy; target not shown in source table. | https://www.marketbeat.com/stocks/NASDAQ/AAPL/forecast/ |
| Wells Fargo | Buy | $300 | 2025-10-31 | Overweight; raised $290→$300. | https://www.marketbeat.com/stocks/NASDAQ/AAPL/forecast/ |
Consensus View - Rating: Buy, Target Price: $307.60 - Average of 5 available PTs (GS/MS/JPM/BAC/WFC).
MSFT - Microsoft Corp.
Broadly Buy; several 1/29/2026 trims on AI capex debate.
| Institution | Rating | Target Price | Last Update | Notes | Source |
|---|---|---|---|---|---|
| Goldman Sachs | Buy | $600 | 2026-01-30 | Lowered from $655 while keeping Buy. | https://za.investing.com/news/analyst-ratings/goldman-sachs-lowers-microsoft-stock-price-target-to-600-on-capex-concerns-93CH-4084224 |
| Morgan Stanley | Buy | $615 | 2026-01-29 | Lowered from $630; Overweight. | https://www.marketbeat.com/stocks/NASDAQ/MSFT/forecast/ |
| JP Morgan | Buy | $550 | 2026-01-29 | Lowered from $575; Overweight. | https://www.marketbeat.com/stocks/NASDAQ/MSFT/forecast/ |
| Bank of America | Buy | $510 | 2026-03-24 | Lowered from $600; Buy. | https://www.marketbeat.com/stocks/NASDAQ/MSFT/forecast/ |
| Citigroup | Buy | $600 | 2026-04-16 | Lowered from $635; Buy. | https://www.marketbeat.com/stocks/NASDAQ/MSFT/forecast/ |
| Wells Fargo | Buy | $641 | 2026-01-29 | Reiterated Outperform; trimmed $645→$641. | https://www.marketbeat.com/stocks/NASDAQ/MSFT/forecast/ |
Consensus View - Rating: Buy, Target Price: $586.00 - Average of all six PTs.
GOOGL - Alphabet Inc.
All six show Buy‑equivalent with recent raises; WFC trimmed in March.
| Institution | Rating | Target Price | Last Update | Notes | Source |
|---|---|---|---|---|---|
| Goldman Sachs | Buy | $375 | 2026-01-13 | Raised $330→$375. | https://www.marketbeat.com/stocks/NASDAQ/GOOGL/forecast/ |
| Morgan Stanley | Buy | $330 | 2025-10-30 | Overweight; raised $270→$330. | https://www.marketbeat.com/stocks/NASDAQ/GOOGL/forecast/ |
| JP Morgan | Buy | $410 | 2026-04-21 | Outperform; raised $400→$410. | https://www.marketbeat.com/stocks/NASDAQ/GOOGL/forecast/ |
| Bank of America | Buy | $370 | 2025-12-02 | Raised $335→$370. | https://www.marketbeat.com/stocks/NASDAQ/GOOGL/forecast/ |
| Citigroup | Buy | $405 | 2026-04-14 | Reiterated Buy; raised $390→$405. | https://www.marketbeat.com/stocks/NASDAQ/GOOGL/forecast/ |
| Wells Fargo | Buy | $361 | 2026-03-06 | Overweight; lowered $397→$361. | https://www.marketbeat.com/stocks/NASDAQ/GOOGL/forecast/ |
Consensus View - Rating: Buy, Target Price: $375.17 - Average of six PTs.
AMZN - Amazon.com Inc.
Uniform Buy‑equivalent; GS most recent cut to $275; WFC top‑end $305.
| Institution | Rating | Target Price | Last Update | Notes | Source |
|---|---|---|---|---|---|
| Goldman Sachs | Buy | $275 | 2026-04-13 | Lowered $280→$275 ahead of Q1 report. | https://za.investing.com/news/stock-market-news/goldman-sachs-lowers-amazon-stock-price-target-to-275-on-aws-growth-93CH-4209559 |
| Morgan Stanley | Buy | $300 | 2026-02-06 | Reiterated Overweight; trimmed $315→$300. | https://www.marketbeat.com/stocks/NASDAQ/AMZN/forecast/ |
| JP Morgan | Buy | $280 | 2026-03-19 | Raised $265→$280; Overweight. | https://www.marketbeat.com/stocks/NASDAQ/AMZN/forecast/ |
| Bank of America | Buy | $298 | 2026-04-20 | Raised $275→$298 ahead of Q1. | https://www.investing.com/news/analyst-ratings/bofa-raises-amazon-stock-price-target-to-298-on-aws-growth-outlook-93CH-4623866 |
| Citigroup | Buy | $285 | 2026-03-25 | Raised $265→$285. | https://www.marketbeat.com/stocks/NASDAQ/AMZN/forecast/ |
| Wells Fargo | Buy | $305 | 2026-03-30 | Overweight; raised $304→$305. | https://www.marketbeat.com/stocks/NASDAQ/AMZN/forecast/ |
Consensus View - Rating: Buy, Target Price: $290.50 - Average of six PTs.
NVDA - NVIDIA Corp.
Broadly Buy; BAC lifted to $300 post‑results; JPM to $265.
| Institution | Rating | Target Price | Last Update | Notes | Source |
|---|---|---|---|---|---|
| Goldman Sachs | Buy | $250 | 2026-02-25 | New target set in Feb. | https://www.marketbeat.com/stocks/NASDAQ/NVDA/forecast/ |
| Morgan Stanley | - | $260 | 2026-02-27 | Target set; rating not shown in source table. | https://www.marketbeat.com/stocks/NASDAQ/NVDA/forecast/ |
| JP Morgan | Buy | $265 | 2026-02-26 | Overweight; raised $250→$265. | https://www.marketbeat.com/stocks/NASDAQ/NVDA/forecast/ |
| Bank of America | Buy | $300 | 2026-02-25 | Raised $275→$300. | https://www.marketbeat.com/stocks/NASDAQ/NVDA/forecast/ |
| Citigroup | Buy | $270 | 2026-01-07 | Reiterated Buy; maintained $270 PT at/after CES. | https://m.investing.com/news/analyst-ratings/citi-reiterates-buy-rating-on-nvidia-stock-maintains-270-price-target-93CH-4435366?ampMode=1 |
| Wells Fargo | Buy | - | 2025-11-28 | Reiterated Overweight; PT not shown. | https://www.marketbeat.com/stocks/NASDAQ/NVDA/forecast/ |
Consensus View - Rating: Buy, Target Price: $269.00 - Average of 5 available PTs (GS/MS/JPM/BAC/C).
META - Meta Platforms Inc.
Limited recent bank-specific visibility from public pages; JPM lifted to $825 on 1/29/2026.
| Institution | Rating | Target Price | Last Update | Notes | Source |
|---|---|---|---|---|---|
| Goldman Sachs | Buy | - | 2025-08-05 | Reiterated Buy; PT not shown. | https://www.marketbeat.com/stocks/NASDAQ/META/forecast/ |
| Morgan Stanley | - | - | - | - | https://www.marketbeat.com/stocks/NASDAQ/META/forecast/ |
| JP Morgan | Buy | $825 | 2026-01-29 | Overweight; raised $800→$825. | https://www.marketbeat.com/stocks/NASDAQ/META/forecast/ |
| Bank of America | - | - | - | - | https://www.marketbeat.com/stocks/NASDAQ/META/forecast/ |
| Citigroup | Buy | - | 2026-01-29 | Reiterated Outperform; PT not shown. | https://www.marketbeat.com/stocks/NASDAQ/META/forecast/ |
| Wells Fargo | - | - | - | - | https://www.marketbeat.com/stocks/NASDAQ/META/forecast/ |
Consensus View - Rating: Buy, Target Price: $825.00 - Based on JPM PT only; others not displayed publicly in source table.
TSLA - Tesla Inc.
Source page confirms coverage by GS and JPM; recent explicit targets not shown on the public page.
| Institution | Rating | Target Price | Last Update | Notes | Source |
|---|---|---|---|---|---|
| Goldman Sachs | - | - | - | - | https://www.marketbeat.com/stocks/NASDAQ/TSLA/forecast/ |
| Morgan Stanley | - | - | - | - | https://www.marketbeat.com/stocks/NASDAQ/TSLA/forecast/ |
| JP Morgan | - | - | - | - | https://www.marketbeat.com/stocks/NASDAQ/TSLA/forecast/ |
| Bank of America | - | - | - | - | https://www.marketbeat.com/stocks/NASDAQ/TSLA/forecast/ |
| Citigroup | - | - | - | - | https://www.marketbeat.com/stocks/NASDAQ/TSLA/forecast/ |
| Wells Fargo | - | - | - | - | https://www.marketbeat.com/stocks/NASDAQ/TSLA/forecast/ |
Consensus View - Insufficient recent PT data on public page.
AVGO - Broadcom Inc.
Public page accessed; specific recent items from the six banks not surfaced on the page snapshot.
| Institution | Rating | Target Price | Last Update | Notes | Source |
|---|---|---|---|---|---|
| Goldman Sachs | - | - | - | - | https://www.marketbeat.com/stocks/NASDAQ/AVGO/forecast/ |
| Morgan Stanley | - | - | - | - | https://www.marketbeat.com/stocks/NASDAQ/AVGO/forecast/ |
| JP Morgan | - | - | - | - | https://www.marketbeat.com/stocks/NASDAQ/AVGO/forecast/ |
| Bank of America | - | - | - | - | https://www.marketbeat.com/stocks/NASDAQ/AVGO/forecast/ |
| Citigroup | - | - | - | - | https://www.marketbeat.com/stocks/NASDAQ/AVGO/forecast/ |
| Wells Fargo | - | - | - | - | https://www.marketbeat.com/stocks/NASDAQ/AVGO/forecast/ |
Consensus View - No recent bank‑specific entries visible on public page.
TSM - Taiwan Semiconductor Manufacturing Co.
Public page accessed; specific recent items from the six banks not surfaced on the page snapshot.
| Institution | Rating | Target Price | Last Update | Notes | Source |
|---|---|---|---|---|---|
| Goldman Sachs | - | - | - | - | https://www.marketbeat.com/stocks/NYSE/TSM/forecast/ |
| Morgan Stanley | - | - | - | - | https://www.marketbeat.com/stocks/NYSE/TSM/forecast/ |
| JP Morgan | - | - | - | - | https://www.marketbeat.com/stocks/NYSE/TSM/forecast/ |
| Bank of America | - | - | - | - | https://www.marketbeat.com/stocks/NYSE/TSM/forecast/ |
| Citigroup | - | - | - | - | https://www.marketbeat.com/stocks/NYSE/TSM/forecast/ |
| Wells Fargo | - | - | - | - | https://www.marketbeat.com/stocks/NYSE/TSM/forecast/ |
Consensus View - No recent bank‑specific entries visible on public page.
Highlights
- AAPL: GS Buy $330 (Apr 20, 2026); JPM Overweight $325 (Jan 30, 2026).
- MSFT: Broad trims on Jan 29, 2026; consensus PT ~$586 across the six.
- GOOGL: JPM lifted to $410 (Apr 21, 2026); GS at $375 (Jan 13, 2026).
- AMZN: GS cut to $275 (Apr 13, 2026); BAC raised to $298 (Apr 20, 2026); WFC at $305 (Mar 30, 2026).
- NVDA: BAC raised to $300 (Feb 25, 2026); JPM to $265 (Feb 26, 2026).
Notes: 1) Ratings mapped to Buy/Hold/Sell as described in Intro. 2) Consensus target is the simple average of available targets from the six requested institutions only; entries marked null were not visible on the public pages or not stated in accessible summaries. 3) If you’d like, I can perform deeper paywalled source checks or add more brokers for AVGO/TSM/META/TSLA to fill remaining gaps.
IPO Calendar
Timeframe: April 24, 2026 to May 24, 2026 (US equity markets)
After a burst of large-cap activity in mid‑April (e.g., Madison Air Solutions on April 16 and Arxis on April 16), issuance is transitioning into late April and May with a mix of industrial/energy and health care deals. X‑Energy priced above range and lists today (April 24), underscoring investor appetite for power and data‑center‑adjacent infrastructure, while the near‑term pipeline tilts toward biopharma (Avalyn Pharma; Salspera). Overall IPO volumes remain selective versus 2025, but execution windows are opening for differentiated, well‑sized offerings as macro volatility stabilizes. (renaissancecapital.com)
X‑Energy, Inc. (XE)
- Expected listing date: April 24, 2026
- Price range: Priced at $23.00 per share (upsized)
- Shares offered: 44,254,659 shares (primary)
- Exchange: Nasdaq (Global Select Market)
- Lead underwriters: J.P. Morgan, Morgan Stanley, Jefferies, Moelis & Company, Cantor Fitzgerald, UBS Investment Bank, TD Securities, Guggenheim Securities, WR Securities, Nomura Securities
- Business summary: Advanced nuclear company developing small modular reactors (Xe‑100 HTGR) and proprietary nuclear fuel to meet rising electricity demand, including AI‑driven data center loads; the company highlights DOE ARDP cost‑share support toward first‑of‑a‑kind deployment. (renaissancecapital.com)
- Notes: Final pricing announced April 23, 2026; listing April 24, 2026. Proceeds and share count reflect the upsized deal (above prior $16–$19 filing range). (x-energy.com)
- Sources: X‑Energy press release – Pricing (April 23, 2026), Renaissance Capital – X‑Energy profile/calendar, SEC S‑1/A (April 15, 2026)
Avalyn Pharma, Inc. (AVLN)
- Expected listing date: Week of April 27, 2026 (TBD)
- Price range: $16.00 – $18.00
- Shares offered: 11,800,000 shares
- Exchange: Nasdaq
- Lead underwriters: Morgan Stanley, Jefferies, Evercore ISI, Guggenheim Securities
- Business summary: Phase 2 biotech developing inhaled antifibrotic therapies for rare respiratory diseases (pulmonary fibrosis). Lead candidates AP01 (inhaled pirfenidone) and AP02 (inhaled nintedanib) aim to improve lung exposure and reduce systemic side effects relative to oral treatments. (renaissancecapital.com)
- Notes: Terms set April 23, 2026; company indicates expected pricing in the week of April 27, 2026, subject to market conditions and SEC effectiveness. (renaissancecapital.com)
- Sources: Renaissance Capital – Avalyn sets terms (April 23, 2026), Renaissance Capital – Avalyn profile
Salspera, Inc. (TKVA)
- Expected listing date: TBD (terms set February 23, 2026)
- Price range: $14.00 – $16.00
- Shares offered: 5,700,000 shares
- Exchange: Nasdaq
- Lead underwriters: Kingswood Capital Markets
- Business summary: Clinical‑stage immuno‑oncology company developing ‘live biopharmaceuticals’ that deliver IL‑2 locally via an engineered, attenuated Salmonella strain (lead program: Saltikva) for solid tumors including metastatic pancreatic cancer. (renaissancecapital.com)
- Notes: On file and marketing since February 23, 2026; timing remains subject to market window and SEC effectiveness. (renaissancecapital.com)
- Sources: Renaissance Capital – Salspera sets terms (Feb 23, 2026), Renaissance Capital – Salspera profile
IPO calendars change frequently; launches, pricing dates, ranges, and share counts can shift—or offerings can be postponed or withdrawn—based on market conditions and SEC review. Data above reflects disclosures and calendars available as of April 24, 2026. For the latest status, confirm against the issuer’s most recent SEC filings and the exchanges’ official calendars. (renaissancecapital.com)
Sources
- Stock Ratings: https://m.investing.com/news/analyst-ratings/citi-reiterates-buy-rating-on-nvidia-stock-maintains-270-price-target-93CH-4435366?ampMode=1, https://www.investing.com/news/analyst-ratings/bofa-raises-amazon-stock-price-target-to-298-on-aws-growth-outlook-93CH-4623866, https://www.marketbeat.com/stocks/NASDAQ/AAPL/forecast/, https://www.marketbeat.com/stocks/NASDAQ/AMZN/forecast/, https://www.marketbeat.com/stocks/NASDAQ/AVGO/forecast/, https://www.marketbeat.com/stocks/NASDAQ/GOOGL/forecast/, https://www.marketbeat.com/stocks/NASDAQ/META/forecast/, https://www.marketbeat.com/stocks/NASDAQ/MSFT/forecast/, https://www.marketbeat.com/stocks/NASDAQ/NVDA/forecast/, https://www.marketbeat.com/stocks/NASDAQ/TSLA/forecast/, https://www.marketbeat.com/stocks/NYSE/TSM/forecast/, https://www.streetinsider.com/news.php?classic=1&id=26332787, https://za.investing.com/news/analyst-ratings/goldman-sachs-lowers-microsoft-stock-price-target-to-600-on-capex-concerns-93CH-4084224, https://za.investing.com/news/stock-market-news/goldman-sachs-lowers-amazon-stock-price-target-to-275-on-aws-growth-93CH-4209559
- IPO Calendar: https://www.renaissancecapital.com/IPO-Center/Calendar, https://www.renaissancecapital.com/IPO-Center/News/117206/Immuno-oncology-biotech-Salspera-sets-terms-for-%2485-million-IPO, https://www.renaissancecapital.com/IPO-Center/News/118343/Airflow-products-manufacturer-Madison-Air-Solutions-prices-IPO-at-%2427-the-h?utm_source=openai, https://www.renaissancecapital.com/IPO-Center/News/118525/Pulmonary-fibrosis-biotech-Avalyn-Pharma-sets-terms-for-%24201-million-IPO, https://www.renaissancecapital.com/Profile/TKVA/Salspera/IPO, https://www.renaissancecapital.com/Profile/XE/X-Energy/IPO, https://x-energy.com/news/x-energy-announces-pricing-of-upsized-initial-public-offering/?utm_source=openai
Disclaimer
This research report is for informational purposes only and does not constitute investment advice. All information is sourced from publicly available data and should be verified independently. Past performance does not guarantee future results.
Generated on: 2026-04-24 at 11:37 UTC
Source: Alpha Signal Monitor - Automated Research System
Contact: For questions about this report, please contact your Alpha Signal Monitor administrator.
Powered by Alpha Signal Monitor | Market Intelligence Through AI